Pathios Therapeutics is a drug discovery and development company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of the acidic TME and the immune cell receptor GPR65. To date, Pathios has raised a total of $58M in venture funding, recently completing a Series B capital raise to advance its lead asset, PTT-4256 into clinical development. Given the ubiquitous nature of the GPR65 pathway in solid cancers this approach is expected to have utility across a broad spectrum of cancers.
Pathios employs a cutting-edge scientific approach to mapping the signalling of GPR65 in primary immune cells based on human genetic insights, transcriptomics and state-of-the-art cellular immunology. By leveraging a range of proprietary insights emerging from this approach, Pathios has identified GPR65 as the key driver of the immunologically-hostile TME, thereby providing the long sought after missing link between and acidic tumor and pro-tumorigenic changes in tumor-infiltrating immune cells.
“Pathios is founded on the simple principle that malignant tumors are characterised by an abnormally low pH that signals to a range of immune cells to fundamentally change their characteristics in a detrimental way for the patient. At the apex of this signalling is the cell-surface receptor, GPR65, which senses the acidic tumor microenvironment and renders usually helpful immune cells as highly immunosuppressive and pro-tumourigenic. Pathios’ approach is focused on developing drugs that block GPR65 to prevent this signalling and unlock the enormous power of multiple arms of the immune system in the fight against cancer. This approach is firmly grounded in human genetic validation, has robust monotherapy potential and is therefore unique amongst approaches in this space.” Dr. Stuart Hughes, Chief Executive Officer, Pathios Therapeutics
Our ground-breaking scientific approach and impressive data presented in downloadable poster presentations.